Telix Establishes Commercial Hub in Geneva, Switzerland

Melbourne (Australia) and Geneva (Switzerland) – 4 October 2021. Telix announces that it has established a new commercial hub in Geneva through its subsidiary, Telix Pharmaceuticals (Switzerland) GmbH.

Telix is pleased to announce that it has established a new commercial hub in Geneva through its subsidiary, Telix Pharmaceuticals (Switzerland) GmbH.

The Company’s Geneva office will become a key locale for Telix’s commercial activities in the EMEA operating region, as well as being the legal entity responsible for commercialisation of Telix’s products in Switzerland.

Telix EMEA CEO Richard Valeix said, “As we rapidly transition to a commercial-stage company, we are continuing to invest in the European region and are establishing a highly experienced biopharma leadership team. Our commercial hub in Geneva will complement the already strong R&D, manufacturing and supply-chain focus of our Belgian team, which is renowned for its industry-leading innovation and deep expertise in radiopharmaceutical development.”

Telix Group CEO Dr. Christian Behrenbruch added, “We see a highly motivated and accessible commercial talent pool in Switzerland, including deep radiopharmaceutical expertise. Switzerland is also a unique European jurisdiction that serves as a benchmark healthcare regulator for many other countries around the globe.”

To read the full press release please click here.

To return to Telix’s homepage please click here.